Vertex Pharmaceuticals Incorporated
VRTX
$552.85
$5.260.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.48% | 59.59% | 30.46% | 3.59% | 128.74% |
| Total Depreciation and Amortization | 9.28% | 15.50% | 15.02% | 1.50% | -4.26% |
| Total Amortization of Deferred Charges | -- | -- | 23.81% | -- | -- |
| Total Other Non-Cash Items | -30.44% | -75.53% | 7.39% | -139.67% | 341.24% |
| Change in Net Operating Assets | 13.14% | 191.14% | -69.19% | -5.02% | 45.15% |
| Cash from Operations | 4.87% | 74.39% | -14.81% | -9.37% | 128.59% |
| Capital Expenditure | 22.99% | -227.76% | -61.34% | -50.37% | -111.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 119.60% | -1,876.82% | 80.98% | 94.58% | 14.16% |
| Cash from Investing | 90.55% | -674.01% | 64.95% | 66.38% | -4.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -7.69% | 74.07% | -- |
| Issuance of Common Stock | -2.85% | 61.68% | 57.43% | -5.95% | -10.73% |
| Repurchase of Common Stock | -19.14% | 18.83% | 69.21% | -196.91% | 0.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 20.00% | 22.22% | 22.22% | -166.67% |
| Cash from Financing | -22.19% | 20.81% | 80.27% | -197.94% | 2.62% |
| Foreign Exchange rate Adjustments | -106.47% | -232.13% | 115.43% | -117.98% | 2,388.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.88% | 268.46% | 120.71% | -105.20% | 106.48% |